Phase 2 Stroke Trial, Recruiting NCT06930638 Sponsor: Medical College of Wisconsin Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT06930638
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 85 years old
  • People who had a stroke at least 6 months ago that affected the cortical or sub-cortical areas of the brain, and who still have weakness on one side of the body as a result
  • People who are able to give informed consent and follow a two-step instruction
  • People who speak English

Who may not be able to join:

  • People who cannot stand up from a chair without physical help from another person (using an assistive device on their own is acceptable)
  • People who have a history of blood clots in their arms or legs, or any condition where compression of the thigh or brief reduction in blood flow would not be safe (for example, wounds on the leg)
  • People who have had ongoing severe COVID-19 symptoms lasting more than 6 months (such as those who were hospitalised due to COVID-19)
  • People who have had a head injury or concussion in the past 6 months
  • People who have another neurological condition in addition to their stroke
  • People who have peripheral vascular disease (a condition affecting blood flow in the limbs)
  • People who have had a heart attack or a heart rhythm problem within the past year
  • People whose resting blood pressure is 180/100 mmHg or higher
  • People who are pregnant or breastfeeding
  • People who have another significant health condition that the lead researcher determines could affect the study or raise safety concerns

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Matthew Durand, PhD, Medical College of Wisconsin

Phone: 414-955-5713

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Medical College of Wisconsin
Registry
ClinicalTrials.gov
Start date
22 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Brachial Artery Flow-Mediated Dilation; Microvascular Vasodilation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov